Press Releases

Epic Sciences Announces Appointment of Dr. Murali Prahalad as President and CEO

SAN DIEGO - August 22, 2013 -- Epic Sciences, Inc. ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced the appointment of Murali K. Prahalad, Ph.D. as president and CEO. Dr. Prahalad was formerly vice president…

Epic Sciences' Research in Prostate Cancer Presented at the 2013 ASCO Genitourinary Cancers Symposium

SAN DIEGO and ORLANDO, FLA. - February 12, 2013 -- Epic Sciences, Inc. ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced the presentation of a research poster at the 2013 Genitourinary Cancers Symposium taking…

Epic Sciences Awarded a Phase II SBIR Contract from NCI/NIH to Develop a Lung Cancer Diagnostic Blood Test

Epic Sciences, Inc., ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced receipt of a Phase II contract from the Small Business Innovation Research (SBIR) program supported by the National Cancer Institute (NCI)…

Epic Sciences Announces Series B Financing to Advance Essential Cancer Diagnostics for Personalized Medicine

Epic Sciences, Inc. ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced today that it has completed a $13 million Series B equity financing. This financing includes new investors Domain Associates, Roche Venture…

Epic Sciences Announces Six Pharma Circulating Tumor Cell Collaborations

San Diego, CA - August 15, 2012 -- Epic Sciences, Inc. ("Epic"), a privately held cancer diagnostics company, announced today that it has established collaborations with six pharmaceutical partners employing Epic's proprietary Circulating Tumor Cell…